Track the Syngene International Limited stock price and the full directors' dealings record of the company, a listed issuer based in India. Shares are listed on the IN market, under the supervision of SEBI (PIT + SAST). Operating in the Health Care sector, Syngene International Limited has published 364 insider filings. Market capitalisation: €160.7bn. The latest transaction was disclosed on 27 December 2024 (Sale). Among the most active insiders: ALOK MEHROTRA. Every trade is free.
364
Insider Decl.
n/a
Thresholds
€29m
95 ops.
Buy Volume
€508m
267 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Syngene International Limited Buy (bullish), based on 8 analysts. Average price target: ₹559.38.
5Σ signal
Buys €29m€508m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,609 of 28,752 companies
56.8
score / 100
Value
43
Quality
71
FCF yld3.4%
Earn yld2.0%
EV/EBITDA18.2x
ROE6.6%
Gross mgn75%
Net mgn8.8%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
5,000 shares@ ₹828.124.2% of flowEquity SharesSEBI:b6609107621d11e80ca48094a56e7106d8df1cdf
25 of 364 declarations
About Syngene International Limited
Syngene International Limited is a company focused on research and development in biopharmaceutical solutions. It provides contract research services to pharmaceutical and biotechnology companies.